Chronic inflammatory demyelinating polyneuropathy (CIDP)
Acquired demyelinating neuropathy · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
An immune-mediated demyelinating polyneuropathy with progressive or relapsing proximal and distal weakness and sensory loss developing over at least 8 weeks, distinguishing it from Guillain-Barre syndrome. It is treatable and responds to immunotherapy.
Red flags
- Rapid progression with respiratory or bulbar involvement
- Failure to respond to standard immunotherapy (reconsider diagnosis/antibodies)
- Underlying paraprotein/POEMS
- Severe disability or falls
- Autonomic involvement
Assessment
Differential diagnosis
- Guillain-Barre syndrome (acute, under 4 weeks)
- Hereditary neuropathy (CMT)
- Paraproteinaemic/anti-MAG neuropathy
- Diabetic polyneuropathy
- Multifocal motor neuropathy
- POEMS syndrome
Investigations
- Nerve conduction studies showing demyelination (conduction block, prolonged latencies)
- CSF analysis (albuminocytological dissociation)
- Serum protein electrophoresis and immunofixation (exclude paraprotein)
- Anti-nodal/paranodal antibodies (NF155, CNTN1) in atypical/refractory cases
- MRI of nerve roots/plexus (hypertrophy, enhancement)
- Nerve biopsy only in selected atypical cases
Management
- Recognise symmetrical proximal and distal weakness with areflexia evolving over more than 8 weeks
- Confirm demyelination on nerve conduction studies
- Support with CSF albuminocytological dissociation
- Exclude paraproteinaemia and mimics
- Start first-line immunotherapy (IVIG, corticosteroids or plasma exchange)
- Assess objective response over weeks and adjust therapy
- Establish maintenance therapy for responders (IVIG or subcutaneous Ig)
- Taper to the lowest effective maintenance dose and periodically test ongoing need
- Provide physiotherapy and functional rehabilitation
- Test for nodal/paranodal antibodies in treatment-resistant cases (may need rituximab)
Drugs & doses
IVIG 2 g/kg over 2-5 days induction, then maintenance e.g. 1 g/kg every 3 weeks
Prednisolone 60 mg PO daily or pulsed high-dose steroids, tapering
Plasma exchange (5 exchanges over 2 weeks) for severe disease
Subcutaneous immunoglobulin for maintenance
Rituximab for anti-paranodal antibody-positive refractory disease
Disposition
Specialist neuromuscular clinic. Day-case or inpatient IVIG. Long-term immunotherapy with treatment-need review.
Complications & pitfalls
- Progressive disability and dependency
- Axonal loss from delayed treatment
- Treatment-related complications (steroid effects, IVIG thrombosis)
- Misdiagnosis delaying effective therapy
- Relapse on withdrawal
Exam pearls
- Time course over 8 weeks separates CIDP from Guillain-Barre syndrome
- CIDP is eminently treatable; do not miss it in progressive neuropathy
- Anti-nodal/paranodal antibody subtypes respond poorly to IVIG but may respond to rituximab
- Always periodically test whether ongoing maintenance therapy is still needed
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.